Active learning repurposes BMS-262084 as a potent TMPRSS2 inhibitor that blocks coronavirus entry
A molecular-dynamics and active-learning workflow prioritized the existing compound BMS-262084 as a nanomolar inhibitor of human TMPRSS2 (IC50 1.82 nM). Cell assays reported inhibition of SARS-CoV-2 variants and other coronavirus entry into Calu-3 lung cells.
Technology: Molecular-dynamics-informed active learning with a target-specific scoring function
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Cell assays reported inhibition of SARS-CoV-2 variants and other coronavirus entry into Calu-3 lung cells.
- Still unknown: BMS-262084 is a known small molecule repurposed here for TMPRSS2; the discovery claim is its target/antiviral activity under tested conditions. Evidence is biochemical and cell-based, not clinical efficacy or safety. Assay concentrations, viral variants and cell systems limit generalization.
- AI role: The active-learning workflow used receptor ensembles and target-specific features to iteratively prioritize compounds for testing; researchers measured purified-enzyme inhibition and viral-entry effects in cell assays. This is AI-assisted repurposing of an existing compound, not de novo molecule design.
Evidence sources: https://www.nature.com/articles/s41467-025-62139-5.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 10 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.